TR201904382T4 - Vajinit tedavisi. - Google Patents
Vajinit tedavisi. Download PDFInfo
- Publication number
- TR201904382T4 TR201904382T4 TR2019/04382T TR201904382T TR201904382T4 TR 201904382 T4 TR201904382 T4 TR 201904382T4 TR 2019/04382 T TR2019/04382 T TR 2019/04382T TR 201904382 T TR201904382 T TR 201904382T TR 201904382 T4 TR201904382 T4 TR 201904382T4
- Authority
- TR
- Turkey
- Prior art keywords
- vaginal
- healthy
- microbiota
- treatment
- vaginitis
- Prior art date
Links
- 201000008100 Vaginitis Diseases 0.000 title abstract 3
- 206010046914 Vaginal infection Diseases 0.000 title abstract 2
- 241000736262 Microbiota Species 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 208000032159 Vaginal inflammation Diseases 0.000 abstract 1
- 208000037009 Vaginitis bacterial Diseases 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- JYIBXUUINYLWLR-UHFFFAOYSA-N aluminum;calcium;potassium;silicon;sodium;trihydrate Chemical compound O.O.O.[Na].[Al].[Si].[K].[Ca] JYIBXUUINYLWLR-UHFFFAOYSA-N 0.000 abstract 1
- 229910001603 clinoptilolite Inorganic materials 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- 239000000284 extract Substances 0.000 abstract 1
- 239000006260 foam Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- -1 pessary Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000000829 suppository Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 208000013464 vaginal disease Diseases 0.000 abstract 1
- 239000000003 vaginal tablet Substances 0.000 abstract 1
- 229940044977 vaginal tablet Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15194288.5A EP3167890A1 (de) | 2015-11-12 | 2015-11-12 | Behandlung von vaginitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201904382T4 true TR201904382T4 (tr) | 2019-04-22 |
Family
ID=54542054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/04382T TR201904382T4 (tr) | 2015-11-12 | 2016-10-25 | Vajinit tedavisi. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20170136060A1 (https=) |
| EP (2) | EP3167890A1 (https=) |
| JP (1) | JP6792420B2 (https=) |
| KR (1) | KR102335607B1 (https=) |
| CN (1) | CN106974932B (https=) |
| AU (1) | AU2016247097B2 (https=) |
| CA (1) | CA2947570C (https=) |
| ES (1) | ES2719223T3 (https=) |
| TR (1) | TR201904382T4 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3524055A1 (de) * | 2018-02-08 | 2019-08-14 | BCSK Biocid GmbH | Antibakterielles und spermizides gleitmittel |
| US20230407365A1 (en) * | 2022-06-21 | 2023-12-21 | Pamela Miles | Diagnostic tool for screening the impact of product ingredients for urogenital microbiomes therapies |
| CN116059177A (zh) * | 2022-12-14 | 2023-05-05 | 迪沙药业集团有限公司 | 一种克林霉素磷酸酯组合物及其制备方法 |
| CN117535208B (zh) * | 2024-01-04 | 2024-03-29 | 四川厌氧生物科技有限责任公司 | 一种卷曲乳杆菌及其在女性生殖道健康中的应用 |
| JP7813333B1 (ja) * | 2024-11-08 | 2026-02-12 | 日本食品化工株式会社 | 膣常在菌叢バランス改善剤及び膣用組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6353146B1 (en) * | 1998-04-20 | 2002-03-05 | Playtex Products, Inc. | Fibrous articles having odor adsorbtion ability and method of making same |
| ES2165139T3 (es) * | 1998-04-30 | 2002-03-01 | Vesely Renata Maria Cavaliere | Composiciones farmaceuticas que contienen lactobacillus brevis y lactobacillus salivarius para el tratamiento de infecciones vaginales. |
| EP1316530B1 (de) * | 1999-04-26 | 2004-12-15 | Tihomir Lelas | Mikronisierte Zoelithe zur Verwendung als pharmazeutisches Mittel |
| KR20060128125A (ko) * | 2005-06-09 | 2006-12-14 | 인하대학교 산학협력단 | 만델산을 유효성분으로 함유하는 질염 치료제 |
| WO2007054085A2 (de) * | 2005-11-11 | 2007-05-18 | Ljubicic, Mijo | Antivirales mittel umfassend tribomechanisch aktiviertes zeolith (tmaz), propolis und kolostrum |
| SI2040837T1 (sl) | 2006-07-04 | 2012-10-30 | Gaston Glock | Postopek za odločenje težkih kovin |
| CN101594888A (zh) * | 2006-12-15 | 2009-12-02 | 欧兰益生公司 | 含有产乳酸细菌的吸收制品 |
| WO2009133413A1 (en) * | 2008-04-28 | 2009-11-05 | Novatech D.O.O. | Formulation based on micronized clinoptilolite as a therapeutic agent for removal of toxins, bacteria and viruses from organism |
| EP2358642B2 (de) * | 2008-11-21 | 2022-12-07 | Froximun AG | Klinoptilolith oder klinoptilolithhaltige gemische |
| KR101198572B1 (ko) * | 2010-07-09 | 2012-11-06 | 경희대학교 산학협력단 | 미생물 감염증 치료 또는 개선용 조성물 |
-
2015
- 2015-11-12 EP EP15194288.5A patent/EP3167890A1/de not_active Withdrawn
-
2016
- 2016-10-19 AU AU2016247097A patent/AU2016247097B2/en not_active Ceased
- 2016-10-25 EP EP16455004.8A patent/EP3167891B1/de active Active
- 2016-10-25 ES ES16455004T patent/ES2719223T3/es active Active
- 2016-10-25 TR TR2019/04382T patent/TR201904382T4/tr unknown
- 2016-11-03 CA CA2947570A patent/CA2947570C/en active Active
- 2016-11-11 CN CN201610997927.6A patent/CN106974932B/zh active Active
- 2016-11-11 US US15/349,727 patent/US20170136060A1/en not_active Abandoned
- 2016-11-11 JP JP2016220187A patent/JP6792420B2/ja not_active Expired - Fee Related
- 2016-11-14 KR KR1020160151167A patent/KR102335607B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3167891A1 (de) | 2017-05-17 |
| CN106974932A (zh) | 2017-07-25 |
| EP3167890A1 (de) | 2017-05-17 |
| BR102016026252A2 (pt) | 2017-05-23 |
| JP2017088603A (ja) | 2017-05-25 |
| CA2947570C (en) | 2021-08-10 |
| CN106974932B (zh) | 2021-05-04 |
| ES2719223T3 (es) | 2019-07-09 |
| US20170136060A1 (en) | 2017-05-18 |
| JP6792420B2 (ja) | 2020-11-25 |
| AU2016247097B2 (en) | 2021-12-02 |
| KR102335607B1 (ko) | 2021-12-06 |
| EP3167891B1 (de) | 2019-01-23 |
| KR20170055932A (ko) | 2017-05-22 |
| AU2016247097A1 (en) | 2017-06-01 |
| CA2947570A1 (en) | 2017-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201904382T4 (tr) | Vajinit tedavisi. | |
| MX2019005379A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
| EP4338803A3 (en) | Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX365159B (es) | Cepa aislada de clonostachys rosea para usarse como un agente de control biologico. | |
| WO2015048689A8 (en) | Inhibitors of bruton's tyrosine kinase | |
| BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
| MX375752B (es) | Inhibidores de tirosina quinasa de bruton. | |
| MX2017005575A (es) | Formulacion farmaceutica de anticuerpos anti-tnf alfa. | |
| TN2017000554A1 (en) | Novel combination for use in the treatment of cancer | |
| BR112015014853A2 (pt) | Formulação farmacêutica, formulação farmacêutica liofilizada, uso de uma formulação farmacêutica e artigo de manufatura | |
| IN2013MU03583A (https=) | ||
| JOP20210269A1 (ar) | تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها | |
| MX2019008544A (es) | Nueva formulacion estable para anticuerpos anti-fxia. | |
| CL2011003327A1 (es) | Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales. | |
| BR112013033759A8 (pt) | Forma de dosagem unitária de um gel de base aquosa de metronidazol mucoadesivo e uso relacionado ao gel de base aquosa de metronidazol | |
| PH12017502112A1 (en) | Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors | |
| CO2020007601A2 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
| MX2018000021A (es) | Composiciones multifasicas. | |
| BR112015027436A2 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
| HK1219690A1 (zh) | 利用抗生素来治疗超重和肥胖患者感染的方法 | |
| BR112018014723A2 (pt) | fantasmas bacterianos para o tratamento de câncer | |
| PH12019500992A1 (en) | Directly tablettable matrix for producing tablets with extended active substance delivery | |
| MX2020000009A (es) | Nuevas formulaciones en capsulas de gelatina blandas de secnidazol y sus usos. | |
| CO2021014253A2 (es) | Formulación de tableta vaginal |